research use only
Cat.No.S4101
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Mitochondrial Metabolism Drug Metabolite |
|---|---|
| Other Carbohydrate Metabolism Inhibitors | 2-DG (2-Deoxy-D-glucose) Bromopyruvic acid (3-BP) Dorzagliatin LY2608204 AZD1656 1-Deoxynojirimycin 4',7-Dimethoxy-5-Hydroxyflavone BI-9787 Eleutherol Kaempferol-3-O-neohesperidoside |
|
In vitro |
DMSO
: 74 mg/mL
(276.86 mM)
Water : 74 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 267.28 | Formula | C10H21NO7 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 83480-29-9 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | AO 128 | Smiles | C1C(C(C(C(C1(CO)O)O)O)O)NC(CO)CO | ||
| Targets/IC50/Ki |
α-glucosidases
|
|---|---|
| In vitro |
Voglibose can inhibit the intestinal α-glucosidases, which are responsible for the digestion of disaccharides such as maltose and sucrose, including maltase and sucrase. The Ki values of this compound for sucrase and maltase are about 106and 105 times smaller than the Km values for sucrose and maltose.
|
| In vivo |
Voglibose (0.2 mg/kg) completely inhibits the insulin response to sucrose in rats. This compound (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose in rats. It (0.2 mg/kg) reduces the carbohydrate-induced increase in blood glucose without causing sustained hypoglycemia in both normal and neonatal streptozotocin-induced diabetic rats. This chemical (0.001%) treatment increases GLP-1 secretion (this compound alone, 1.6-fold; Alogliptin plus Voglibose, 1.5-fold), while it decreases plasma glucose-dependent insulinotropic polypeptide (GIP) (this compound alone, 30%; Alogliptin plus voglibose, 29%) in prediabetic db/db mice after 3 weeks. It (0.001%) treatment decreases plasma DPP-4 activity by 15% in prediabetic db/db mice. This compound (0.001%) treatment increases plasma insulin by 1.8-fold and decreases plasma glucagon by 8% in prediabetic db/db mice. It (0.001% and 0.005%) stimulates GLP-1 secretion in ob/ob mice, as evidenced by the 1.3- to 1.5-fold increase in plasma active plus inactive amidated GLP-1 levels. This chemical (0.001% and 0.005%) decreases plasma DPP-4 activity unexpectedly by 40% to 51% in ob/ob mice, resulting from reduced plasma DPP-4 concentrations. It (0.001% and 0.005%) increases GLP-1 content by 1.5- to 1.6-fold and 1.4- to 1.6-fold in the lower intestine and colon, respectively, in ob/ob mice.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01055652 | Completed | Type 2 Diabetes Mellitus |
AstraZeneca|Bristol-Myers Squibb |
January 2010 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.